IS

IsoPlexis CorpNASDAQ ISO Stock Report

Last reporting period 31 Dec, 2022

Updated —

Last price

Market cap $B

0.03

Micro

Exchange

XNAS - Nasdaq

ISO Stock Analysis

IS

Uncovered

IsoPlexis Corp is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-45/100

Low score

Market cap $B

0.03

Dividend yield

Shares outstanding

39.535 B

IsoPlexis Corp. engages in the development of curative medicines and personalized therapeutics. The company is headquartered in Branford, Connecticut and currently employs 459 full-time employees. The company went IPO on 2021-10-08. The firm is engaged in building solutions to develop curative medicines and personalized therapeutics. The firm's single-cell proteomics systems reveal biological activity in small subsets of cells, allowing researchers to connect directly to in-vivo biology and develop precise and personalized therapies. Its focuses on developing applications of its platform for cancer immunology and cell and gene therapy. The firm's platform is comprised of IsoLight and IsoSpark instruments, IsoCode and CodePlex chip consumables, and IsoSpeak software. Its IsoLight and IsoSpark instruments are designed to be automated benchtop proteomic hubs. Its IsoCode chips use its technology proteomic barcoding to capture single-cell protein information. Its CodePlex chips technology is used to test multiplexed bulk proteins. IsoSpeak software provides automated data analysis and accelerated insights. Its subsidiary includes IsoPlexis UK Limited.

View Section: Eyestock Rating